Paradigm4’s Marilyn Matz and Zachary Pitluk discuss the challenges of integrating data from heterogeneous sources and how the company’s plaform and apps combine the cutting edge of computer science and a sensibility geared toward the unique needs of pharma and biopharma to provide end-to-end solutions.
Recent news that the US Food and Drug Administration (FDA) will ask cell and gene therapy (CGT) developers to provide more consistent evidence with their submissions has resulted in drug makers delaying development plans — and working on new ways to address the agency’s concerns
Paradigm4 announces the general availability of flexFS, a hyperscale file system designed for AI/ML and large file data workloads, providing unparalleled throughput at 50% lower cost
Popular opinion is that two big shifts have changed the game for bioinformatics. The first is a technology development—single cell ‘omics—that began just over 10 years ago, the other is a more recent move to a new model of drug discovery that looks to leverage the vast amounts of human
